We are live on ! Find out more
NRSNW icon

NeuroSense Therapeutics Warrant
NRSNW

3 hedge funds and large institutions have $10.4K invested in NeuroSense Therapeutics Warrant in 2026 Q2 according to their latest regulatory filings, with funds opening new positions, increasing their positions, 1 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 3 → 3 (0)

68% less capital invested

Capital invested by funds: $32.8K → $10.4K (-$22.4K)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
3
Holders Change
–
Holders Change %
0%
% of All Funds
0.04%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
1
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
CS
Clear Street
New York
-$43

NRSNW Hedge Fund Activity: Q2 2026 in Review

3 of the 8,343 institutional investors tracked by Wall St. Rank reported a position in NeuroSense Therapeutics Warrant (NRSNW) for Q2 2026, worth a combined $10.4K — down 68% from $32.8K a quarter earlier.

Fund positioning in NRSNW was balanced in Q2 2026: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 1 trimmed.

The largest seller was Clear Street, cutting an estimated $43.

  • 3 institutional investors held NeuroSense Therapeutics Warrant (NRSNW) as of Q2 2026, unchanged from Q1 2026.
  • Funds reported $10.4K of NeuroSense Therapeutics Warrant stock for Q2 2026, down 68% quarter-over-quarter.
  • 0 funds opened new NeuroSense Therapeutics Warrant positions in Q2 2026 and 0 closed out.
  • The largest NeuroSense Therapeutics Warrant seller in Q2 2026 was Clear Street, an estimated $43 sold.

Based on aggregated 13F filings for Q2 2026.